Small Business: Therapeutic Development for Developmental, Psychiatric, and Substance Use Disorders – NPE-10
This review panel evaluates SBIR/STTR applications focused on basic and clinical drug discovery for developmental cognitive disorders, psychiatric and mood disorders, eating and sleep disorders, and substance use disorders. Areas of emphasis include medicinal chemistry, preclinical therapeutic development, toxicology, and selected clinical studies designed to establish proof of principle for new therapies or for repurposing existing drugs. Therapeutic approaches reviewed by the panel include small molecules and biologics, including molecular engineering approaches, gene and stem cell therapies, and proteins or neuropeptides that modulate neuroreceptors, transporters, and signal transduction pathways.
Review Dates
A roster for the panel will be posted here, at least 30 days prior to the review meeting
Topics
- Developmental mental and cognitive disorders such as autism spectrum disorder, Down syndrome, fragile X syndrome, and other congenital cognitive disorders/impairment
- Psychiatric disorders such as obsessive compulsory disorders, psychosis, schizophrenia, etc.
- Mood and anxiety disorders such as depression, anhedonia, bipolar disorder, post-traumatic stress disorder (PTSD), suicide, etc.
- Neurodegenerative diseases-accompanied neuropsychiatric symptoms including aggression, depression, anxiety, apathy, agitation, psychosis, etc.
- Sleep disorders
- Alcoholism and substance use disorders
- Eating disorders
